Illumina (NASDAQ: ILMN)shareholders have basked in the success of the company's NovaSeq system. The company enjoyed a tremendous year in 2017thanks largely to a better-than-expected rollout of the gene-sequencing system. Heading into the first quarter of 2018, there was every reason to anticipate that the momentum would continue.
Illumina Inc. First-Quarter Results: NovaSeq Still the Gift That Keeps on Giving
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться